Auditory Slow Wave Enhancement in Parkinson Disease and Mild Cognitive Impairment

Parkinson Disease Clinical Trial

— PDMCI-TS  

Official title:

Assessing Effects of Auditory Slow Wave Enhancement on Symptoms and Biomarker Levels in Parkinson Disease and Mild Cognitive Impairment: A Randomized, Double-Blind and Placebo- Controlled Crossover Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04736017
• Other study ID #: PDMCI-TS
• Status: Recruiting
• Phase: N/A
• Start date: April 1, 2021
• Est. completion date: March 31, 2024

Study information

• Verified date: November 2022
• Source: University of Zurich
• Contact: Jana Horlacher, MD
• Phone: +41432535022
• Email: jana.horlacher[@]usz.ch
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study aims to assess the efficacy of auditory slow-wave sleep (SWS) enhancement in PD patients and patients with amnestic MCI. Patients will be randomized to two groups: Group 1 will first be treated with auditory stimulation for two weeks and then - after a washout period - switched to two weeks of sham stimulation. Group 2 will first receive sham stimulation for two weeks and then - after a washout period - switch to two weeks of auditory stimulation treatment. The washout period in between will be 2-4 weeks.

Description:

The study is a randomized, double-blind, sham-controlled cross-over trial to assess the efficacy of auditory slow-wave sleep (SWS) enhancement in PD patients and patients with amnestic MCI. The screening phase includes entry questionnaires about inclusion/exclusion criteria, sleep quality, chronotype, and handedness, and 1-4 screening nights at home with the TSB Axo, to allow for stimulation optimization. One of the screening nights will be extended to screen for sleep apnea and periodic limb movements during sleep using an ambulatory screening device. Upon final inclusion, 24 PD and 24 MCI patients will be enrolled in the study for an overall period of 6-8 weeks (not including screening phase). Patients will receive 2 weeks of auditory SWS enhancement and 2 weeks of sham stimulation (only device application, no tones played) in a counter-balanced cross-over design, with a 2-4 week washout period during cross-over. Study visits will be performed immediately before and after each intervention period, i.e. after 2 weeks of auditory stimulation or sham stimulation, respectively. Study visits will include standardized clinical examinations, symptom questionnaires, blood sampling after intervention and screening for adverse events by a study physician. Study visits will take place at the Department of Neurology, University Hospital Zurich.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 48
• Est. completion date: March 31, 2024
• Est. primary completion date: March 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• PD: Diagnosis of PD along international criteria, with mild to moderate disease severity (Hoehn and Yahr scale, stages ll-lll)

• PD: Ability to apply the intervention for the duration of study

• MCI: Diagnosis of MCI along international criteria, with a predominant amnestic presentation (single- or multi-domain amnestic MCI)

• MCI: Presence of a cohabitant person who could assist with the application

• MCI: Ability to apply the intervention for the duration of study, with assistance of co-habitant if needed

PD and MCI:

• Age above 18 years

• Informed consent as documented by signature

• Stable home situation (e.g. long-term place to live) that allows for reliable application of intervention for the duration of the study

• Sufficient German language comprehension to follow the study procedures and answer all questions related to the study outcomes

• Dosing of dopaminergic, cholinergic, and other PD or MCI medication must have been stable for at least 14 days prior to start of the first intervention

• Negative pregnancy test during screening (except in women who are surgically sterilized/hysterectomized or postmenopausal for longer than 1 year)

Exclusion Criteria:

• PD: Presence of neurologic, psychiatric, or sleep disorders (others than associated with PD)

• PD: Parkinsonism without response to levodopa; Atypical Parkinsonian syndromes

• PD: Cognitive impairment (Montréal Cognitive Assessment [MoCA] <24)

• MCI: Present diagnosis of a neurological (other than MCI) or interfering psychiatric disease or sleep disorder (e.g. sleep apnoea syndrome, restless legs syndrome)

PD and MCI:

• Severe medical conditions as renal insufficiency, liver failure or congestive heart failure

• Regular use of the following drugs: Benzodiazepines and other central nervous system (CNS)-depressant substances, melatonin and other sleep inducing substances, approved drugs for Alzheimer-type dementia (acetylcholine-esterase inhibitor, memantine)

• Inability to hear the tones produced by the TSB Axo

• Skin disorders/problems/allergies in face/ear area that could worsen with electrode application

• Known or suspected drug- or medication abuse

• Known or suspected non-compliance

• Participation in another study with investigational drug or investigational medical devices within the 30 days preceding and during the present study

• Previous enrolment in the current study

• Enrolment of the investigator, his/her family members, employees and other dependent persons

• Shift work (work during the night)

• Travelling more than 2 time zones in the last month before intervention starts or during intervention (start of intervention will be adapted to fit with this criteria)

• Substance or alcohol abuse (i.e. > 0.5 l wine or 1 l beer per day)

• High caffeine consumption (> 5 servings/day; including coffee, energy drink)

• Implanted deep brain stimulation electrodes

• Women who are pregnant or breast feeding

• Intention to become pregnant during the course of the study

• Lack of safe contraception, defined as: Female patients of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases

Related Conditions & MeSH terms

• Cognitive Dysfunction
• Mild Cognitive Impairment
• Parkinson Disease

Intervention

Device:
• TSB Axo
The TSB Axo is a wearable biosignal recording device combined with an auditory stimulation. The device consists of pre-gelled biosignal electrodes, headphones integrated in a headband, and a biosignal processing module.

Locations

Country	Name	City	State
Switzerland	University Hospital Zurich, Neurology department	Zurich

Sponsors (1)

Lead Sponsor	Collaborator
University of Zurich

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Difference in objective EDS	Difference in objective excessive daytime sleepiness (EDS), measured with Multiple Sleep Latency Test (MSLT; minutes), in Parkinson patients	assessed after each intervention (day 15 of each intervention)
Primary	Difference in verbal episodic memory performance	Difference in verbal episodic memory performance, measured with the Hopkins Verbal Learning Test (HVLT; score ranges from 0 to 12, higher scores indicate better performance) delayed recall, in Mild Cognitive Impairment patients	assessed after each intervention (day 15 of each intervention)
Secondary	Subjective EDS	Change in subjective excessive daytime sleepiness (EDS), measured with the Epworth Sleepiness Scale (ESS; score ranges from 0 to 24, higher scores indicate greater EDS)	assessed before and after each intervention (day 1 and 15 of each intervention)
Secondary	Sustained attention	Sustained attention, measured with the Sustained Attention to Response Task (SART)	assessed after each intervention (day 15 of each intervention)
Secondary	Vigilance	Vigilance, measured with the Psychomotor Vigilance Task (PVT)	assessed after each intervention (day 15 of each intervention)
Secondary	Subjective nocturnal sleep quality	Subjective nocturnal sleep quality, measured with the Parkinson's Disease Sleep Scale -2 (PDSS-2; score ranges from 0 to 60, higher scores indicate worse sleep quality) in PD patients and Pittsburgh Sleep Quality Index (PSQI; score ranges from 0 to 21, higher scores indicate worse sleep quality) in MCI patients	assessed before and after each intervention (day 1 and 15 of each intervention)
Secondary	Executive Function and attention	Executive function (mental flexibility, verbal fluency, motor programming, sensitivity to interference, working memory, psychomotor processing speed), measured with the Trail Making Test (TMT; in seconds) B/A, the Regensburger Wortflüssigkeitstest (RWT; phonematic and semantic verbal fluency; in word count), the Luria's motor sequence test, the Victoria Stroop Task, the 2-back task, and the TMT A	assessed after each intervention (day 15 of each intervention)
Secondary	Plasma biomarkers	Plasma levels of protein accumulation (aSyn, beta-amyloid 40 and 42 [Aß40, Aß40], tau, phosphorylated tau [p-tau]), neurodegeneration (neurofilament light chain; NFL), and synaptic and inflammatory markers	assessed after each intervention (day 15 of each intervention)
Secondary	Subjective sleep quality	Subjective sleep quality measured with a Visual Analog Scale (VAS) on a scale from very poor to very good	assessed every morning during the intervention period (days 1-15 of each intervention)
Secondary	Subjective mood	Subjective mood during daytime measured with a Visual Analog Scale (VAS) on a scale from very poor to very good	assessed every evening during the intervention period (days 1-14 of each intervention)
Secondary	Subjective momentary sleepiness	Subjective momentary sleepiness measured with Karolinska Sleepiness Scale (KSS; score ranges from 1 to 9, higher scores indicate greater momentary sleepiness)	assessed every evening during the intervention period (days 1-14 of each intervention)
Secondary	Digital biomarkers	tapping behavior on tablet	assessed every day during the intervention (days 1-15 of each intervention)
Secondary	Sleep intensity	Sleep intensity, represented by Slow Wave Activity/ Slow Wave Energy (SWA/SWE), calculated from EEG recordings obtained every night at home with a frontal EEG electrode of the TSB Axo	assessed continuously during the intervention period (days 1-15 of each intervention)
Secondary	Depressive symptoms	Depressive symptoms, indicated by the Hospital Anxiety and Depression Scale (HADS; score ranges from 0 to 21, higher scores indicate more depressive symptoms), in MCI patients	assessed before and after each intervention (day 1 and 15 of each intervention)
Secondary	Verbal episodic and visuospatial memory function	Verbal episodic and visuospatial memory function, measured with the Hopkins Verbal Learning Test (HVLT; score ranges from 0 to 12, higher scores indicate better performance), and Brief Visuospatial Memory Test (BVMT; score ranges from 0 to 12, higher scores indicate better performance), in MCI patients	assessed after each intervention (day 15 of each intervention)
Secondary	Quality of life (VAS)	Quality of life, measured with a Visual Analog Scale (VAS) on a scale from very poor to very good, in Parkinson patients	assessed before and after each intervention (day 1 and 14, day 29 and 42)
Secondary	Motor symptoms	Motor symptoms, assessed with the Unified Parkinson's Disease Rating Scale (UPDRS) lll remote version (on tablet; score ranges from 0 to 104, higher scores indicate worse motor symptoms), in Parkinson patients	assessed before and after each intervention, in the morning prior to dopaminergic medication intake (day 1 and 14 of each intervention)
Secondary	Focused motor assessment	Assessment of hand/finger movements, in Parkinson patients	assessed on day 4 of each intervention
Secondary	Overnight memory consolidation	Overnight memory consolidation, assessed with a word-pair task and finger tapping sequence test in PD and MCI patients	assessed in the evening of day 13 and in the morning of day 14
Secondary	Overnight restoration inhibitory control	Overnight restoration of inhibitory control, assessed with the Go/NoGo Task (GNG) in PD and MCI patients	assessed in the evening of day 13 and in the morning of day 14
Secondary	Overnight restoration working memory	Overnight restoration of the working memory, assessed by the 2-back task in PD and MCI patients	assessed in the evening of day 13 and in the morning of day 14
Secondary	Overnight restoration vigilance	Overnight restoration of vigilance, assessed by the Psychomotor Vigilance Test (PVT) in PD and MCI patients	assessed in the evening of day 13 and in the morning of day 14